High economic investment and increased logistical costs to comply with the maximum levels of cross-contamination in non-target feed if such levels are very low is likely to result in a reduction of the production of medicated feed. In addition, the EMA Advice of 28 August 2020 on implementing measures under Article 106(6) of Regulation (EU) 2019/6 of the European Parliament and of the Council [Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC (OJ L 4, 7.1.2019, p. 43, ELI: http://data.europa.eu/eli/reg/2019/6/oj).] on veterinary medicinal products – scientific problem analysis and recommendations to ensure a safe and efficient administration of oral veterinary medicinal products via routes other than medicated feed [EMA/CVMP/508559/2019.], concludes that it may also result in an increased recourse to methods of oral administration of antimicrobial active substances other than medicated feed, such as the administration on the surface of solid feed, that may increase the risk of AMR and the inability to treat certain bacterial infections in certain species due to the absence of other appropriate routes of administration, for example, in aquaculture. The maximum levels of cross-contamination should, therefore, not be detrimental to the production of medicated feed, in particular, by small and medium-sized feed manufacturing plants, excluding them in practice from the production of medicated feed, which would result in possible issues for public health, and animal health and welfare. It is, therefore, appropriate to establish a maximum level of cross-contamination that is strict but also feasible to achieve by applying good practices to minimise cross-contamination. In addition to the Opinions of 15 September 2021, the experience gained in the Member States in applying national law indicates that a cross-contamination level in the non-target feed of 1 % of the active substance in the medicated feed, represents a good balance between feasibility and AMR control. Intermediate products contain higher concentrations of active substances than medicated feed. Therefore, where non-target feed is manufactured, processed, stored or transported after the manufacturing, processing storage or transport of intermediate products, a cross-contamination level of 1 % of the substance to be contained in the derived medicated feed, should apply.
Recital 10, Regulation (EU) 2024/1229
In forcesince 20 Feb 2024
- celex=32001L0082